• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets.

作者信息

Messmore H L, Griffin B, Fareed J, Coyne E, Seghatchian J

机构信息

Department of Medicine, Hines VA Hospital, Illinois 60141.

出版信息

Ann N Y Acad Sci. 1989;556:217-32. doi: 10.1111/j.1749-6632.1989.tb22505.x.

DOI:10.1111/j.1749-6632.1989.tb22505.x
PMID:2472085
Abstract

Heparin, low molecular weight heparins, and heparinoids were studied for their ability to inhibit the aggregation of platelets by various agonists and for their ability to adhere to collagen. Heparin was a very effective inhibitor of aggregation with collagen and with ristocetin as it was with adhesion to collagen. The heparinoids showed little effect on aggregation or adhesion. Heparan sulfate and pentosan polysulfate did show slight inhibitory activity against collagen aggregation and adhesion and both interacted with the antibody induced by heparin therapy. It is of interest that dermatan sulfate and the pentasaccharide were almost inert in these experiments, and are unlikely to induce bleeding by inhibition of platelet function. It is highly probable that interference with the interaction of von Willebrand factor with platelets and collagen is a major mechanism for bleeding in the heparinized patient.

摘要

相似文献

1
In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets.
Ann N Y Acad Sci. 1989;556:217-32. doi: 10.1111/j.1749-6632.1989.tb22505.x.
2
Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins.类肝素与血小板的相互作用:与肝素和低分子量肝素的比较。
Semin Thromb Hemost. 1991;17 Suppl 1:57-9.
3
Platelet aggregation in humans and nonhuman primates: relevance to xenotransplantation.人类和非人类灵长类动物的血小板聚集:与异种移植的相关性。
Xenotransplantation. 2012 Jul-Aug;19(4):233-43. doi: 10.1111/j.1399-3089.2012.00712.x.
4
Effect of heparin and heparinoids on platelet aggregation.肝素及类肝素对血小板聚集的作用。
Folia Haematol Int Mag Klin Morphol Blutforsch. 1984;111(6):750-60.
5
Low molecular weight heparin as an anticoagulant for in vitro platelet function studies.低分子量肝素作为体外血小板功能研究的抗凝剂。
Thromb Res. 1990 Feb 15;57(4):601-9. doi: 10.1016/0049-3848(90)90077-p.
6
The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls.普通肝素、低分子量肝素和类肝素对重症监护患者及健康对照者血小板的促聚集和增强作用。
Eur J Haematol. 1997 Apr;58(4):279-85. doi: 10.1111/j.1600-0609.1997.tb01667.x.
7
[Effect of heparin on platelet aggregation in vitro].[肝素对体外血小板聚集的作用]
Folia Haematol Int Mag Klin Morphol Blutforsch. 1984;111(6):735-49.
8
Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood.帕米普明,一种低分子量肝素,可防止人全血中血小板 - 白细胞聚集体的P - 选择素依赖性形成。
Thromb Haemost. 2007 Jun;97(6):965-73. doi: 10.1160/th06-12-0680.
9
Effect of heparin on platelet monolayer adhesion, aggregation and production of malondialdehyde.
Thromb Res. 1982 Apr 1;26(1):31-41. doi: 10.1016/0049-3848(82)90148-7.
10
Effects of unfractionated and low molecular weight heparin on platelet-induced thrombin formation time and platelet adhesion.普通肝素和低分子量肝素对血小板诱导的凝血酶形成时间及血小板黏附的影响。
Semin Thromb Hemost. 1993;19 Suppl 1:22-8.

引用本文的文献

1
Fondaparinux: use in thromboprophylaxis of acute medical patients.磺达肝癸钠:用于急性内科患者的血栓预防
Drugs Aging. 2008;25(1):81-8. doi: 10.2165/00002512-200825010-00009.
2
Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.磺达肝癸钠:关于其在预防大型骨科手术后静脉血栓栓塞症中应用的综述
Drugs. 2004;64(14):1575-96. doi: 10.2165/00003495-200464140-00005.
3
Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.依诺肝素的药效学和药代动力学特性:对临床实践的意义。
Clin Pharmacokinet. 2003;42(12):1043-57. doi: 10.2165/00003088-200342120-00003.
4
Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.达肝素:其在预防和治疗血栓栓塞性疾病方面的药理特性及临床疗效的最新进展
Drugs. 2000 Jul;60(1):203-37. doi: 10.2165/00003495-200060010-00010.
5
Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations.低分子量肝素(类肝素)。临床研究与实用建议。
Drugs. 1997 May;53(5):736-51. doi: 10.2165/00003495-199753050-00002.
6
Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.达肝素钠。其药理学及在预防和治疗血栓栓塞性疾病中的临床应用综述。
Drugs. 1996 Aug;52(2):276-305. doi: 10.2165/00003495-199652020-00011.
7
Physiological changes due to age. Implications for the prevention and treatment of thrombosis in older patients.年龄导致的生理变化。对老年患者血栓形成的预防和治疗的影响。
Drugs Aging. 1994 Jul;5(1):20-33. doi: 10.2165/00002512-199405010-00003.
8
Inhibition of coagulation and platelet adhesion to extracellular matrix by unfractionated heparin and a low molecular weight heparin.普通肝素和低分子量肝素对凝血及血小板与细胞外基质黏附的抑制作用
Blut. 1990 Nov;61(5):289-94. doi: 10.1007/BF01732879.